Pfizer Looks To Buy Icagen To Fold Into Neusentis Pain Research Unit
Pfizer plans to buy its pain partner in a deal valued at $56 million, including the 11% of shares the big pharma already owns in Icagen.
Pfizer plans to buy its pain partner in a deal valued at $56 million, including the 11% of shares the big pharma already owns in Icagen.